Ricardo Ayala, MD
Neurology · Tallahassee, FLNPI 1699742767
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 966 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 58 manufacturers, the largest accounting for just 9.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,592 and has fallen 66.7% since, to $1,196 in 2025.
Across 966 payments — averaging $16.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- SK Life Science, Inc.$1K
- Novartis$1K
- UCB, Inc.$886
- Greenwich Biosciences, Inc.$865
- Jazz Pharmaceuticals Inc.$798
- plus $10K from 52 others
Across 107 payments — averaging $64,605 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$3.9M
- Eli Lilly$2.8M
- Biogen$104K
- UCB SA$40K
- EMD Serono, Inc.$24K
- Neurocrine Biosciences, Inc.$13K
- plus $19K from 4 others
What the payments were for
- Speaking & faculty fees$360%
- Food & beverage$16,13299%
- Education$1871%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,354 in reported general payments places this provider in the 80th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 27 | $385,661 |
| XcopriCenobamate | 178 | $267,347 |
| FycompaPerampanel | 194 | $253,566 |
| EpidiolexCannabidiol (Cbd) | 60 | $229,165 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 13 | $191,872 |
| Nurtec OdtRimegepant Sulfate | 100 | $185,067 |
| Emgality PenGalcanezumab-Gnlm | 227 | $178,439 |
| AptiomEslicarbazepine Acetate | 77 | $144,875 |
| Lacosamide | 626 | $122,253 |
| Kesimpta PenOfatumumab | 12 | $109,525 |
| Lamictal XrLamotrigine | 50 | $91,356 |
| ValtocoDiazepam | 43 | $80,894 |
| Aimovig AutoinjectorErenumab-Aooe | 100 | $77,679 |
| FingolimodFingolimod Hcl | 25 | $75,724 |
| Levetiracetam | 813 | $40,018 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPanzyga, Nurtec Odt, Lyrica | $514 | $391,589137 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $503 | $385,66127 claims |
| SK Life Science, Inc.Xcopri | $1,310 | $267,347178 claims |
| Eisai Inc.Fycompa | $527 | $253,566194 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $230 | $144,87577 claims |
| Neurelis, Inc.Valtoco | $654 | $80,89443 claims |
| AbbVieUbrelvy, Qulipta, Namzaric | $1,527 | $63,83757 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $79 | $30,03617 claims |
| Lilly USA, LLCCymbalta | $639 | $6,15611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,434 neurology providers in Florida.
Other neurology in Tallahassee
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
- Mark CascioneTampa$1.2M
- Lance KimOcala$1M
- Tuan VuTampa$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.